A5051375301- Cancer Immunotherapy and Biomarkers
- Ubiquitin and proteasome pathways
- Pancreatic and Hepatic Oncology Research
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Neuroblastoma Research and Treatments
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- Glioma Diagnosis and Treatment
- Microtubule and mitosis dynamics
- Thyroid Cancer Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Cancer-related Molecular Pathways
- ATP Synthase and ATPases Research
- Cancer, Hypoxia, and Metabolism
Mayo Clinic in Arizona
2021-2024
Mayo Clinic
2020-2024
Center for Drug Evaluation and Research
2022
In many cancers, nivolumab in combination with ipilimumab improves response rates compared either agent alone, but the has not been evaluated childhood cancer. We conducted a phase I/II trial of plus children and young adults recurrent/refractory solid tumors.ADVL1412, Part C assessed safety at two dose levels (DL): DL1 1 mg/kg each drug DL2 3 ipilimumab. D recommended II (RP2D) Ewing sarcoma, rhabdomyosarcoma, osteosarcoma. E tested DL3 (1 ipilimumab) sarcoma rhabdomyosarcoma. Tumor was...
Abstract On September 17, 2021, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for treatment of adult and pediatric patients 12 years age older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy who are radioactive iodine (RAI)-refractory ineligible. This is first approval RAI-refractory DTC have in DTC. The was based on data from COSMIC-311 (Study XL184-311, NCT03690388), an international, randomized,...
Abstract Background Outcomes for children with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are poor, new therapies needed. Pevonedistat is an inhibitor of the NEDD‐8 activating enzyme, a key regulator ubiquitin proteasome system that responsible protein turnover, degradation regulating cell growth survival. Procedure We evaluated feasibility, toxicity, pharmacokinetics (PK) pevonedistat (20 mg/m 2 days 1, 3, 5) in combination azacitidine,...
Abstract Background Ramucirumab is a monoclonal antibody that binds the extracellular domain of vascular endothelial growth factor receptor (VEGFR‐2) and prevents binding VEGF ligands. Based on population pharmacokinetic (PK) analysis correlation with efficacy in adults, target steady state trough concentration ( C ss,min ) ≥ 50 µg/mL was established. Procedures This phase 1 trial (ADVL1416) used rolling six design PK primary endpoint to define recommended 2 dose (RP2D) ramucirumab children...
10019 Background: Pevonedistat (PEV), a first in class inhibitor of NEDD8 activating enzyme (NAE), prevents the activation Cullin-RING ligases (CRL) necessary for proteasome mediated degradation key regulatory proteins important cell survival. In adults with solid tumors, maximum tolerated dose (MTD) combination chemotherapy is 20-25 mg/m 2 . Antitumor activity PEV has been demonstrated preclinical models childhood cancer. vivo additive IRN and alkylating agents. The objectives this study...
<div>AbstractPurpose:<p>In many cancers, nivolumab in combination with ipilimumab improves response rates compared either agent alone, but the has not been evaluated childhood cancer. We conducted a phase I/II trial of plus children and young adults recurrent/refractory solid tumors.</p>Patients Methods:<p>ADVL1412, Part C assessed safety at two dose levels (DL): DL1 1 mg/kg each drug DL2 3 ipilimumab. D recommended II (RP2D) Ewing sarcoma, rhabdomyosarcoma,...
<div>AbstractPurpose:<p>In many cancers, nivolumab in combination with ipilimumab improves response rates compared either agent alone, but the has not been evaluated childhood cancer. We conducted a phase I/II trial of plus children and young adults recurrent/refractory solid tumors.</p>Patients Methods:<p>ADVL1412, Part C assessed safety at two dose levels (DL): DL1 1 mg/kg each drug DL2 3 ipilimumab. D recommended II (RP2D) Ewing sarcoma, rhabdomyosarcoma,...
<p>Supplementary Figure 1. Nivolumab (A) and Ipilumumab (B) peak trough concentrations in treatment cycles 1 – 4.</p>
<p>Supplementary information</p>
<p>Supplementary information</p>
<p>Supplementary Figure 1. Nivolumab (A) and Ipilumumab (B) peak trough concentrations in treatment cycles 1 – 4.</p>
10018 Background: Outcomes for children with relapsed/refractory (R/R) AML and MDS are poor new therapies needed. Pevonedistat is an inhibitor of the NEDD-8 activating enzyme, a key regulator ubiquitin proteasome system that responsible protein turnover, cell growth survival. In preclinical models, pevonedistat was synergistic cytarabine (AraC) azacitidine (aza). The combination + aza in adults demonstrated improved responses compared to either single agent. We evaluated feasibility,...